 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...6364656667686970717273...235236» |
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., zolbetuximab (IMAB362) / Astellas
Metastases: Positive study of zolbetuximab (claudin 18.2 Ab) plus FOLFOX for 1st line treatment in Claudin expressing stage IV gastroesophageal cancer - Shitara et al SPOTLIGHT trial LBA292 #gi23 (Twitter) - Jan 19, 2023
- ||||| Metastases: Kicking off oral abstract session #GI23 with results from SPOTLIGHT testing addition of zolbetuximab to mFOLFOX6 in advanced/metastatic gastric or GEJ adenoca (CLDN18.2+/HER2-). Primary endpoint PFS met (Twitter) - Jan 19, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Metastases: SPOTLIGHT on Zolebetuximab + FOLFOX targeting CLDN18.2. Found to be superior (PFS/OS) to chemo alone in Her2 neg advanced gastric cancer. A NEW STANDARD OF CARE How does it fit in age of immunotherapy? #GI23 (Twitter) - Jan 19, 2023
- |||| Late-breaking abstract: LBA Zolbetuximab +mFOLFOX6 in 1L mG/GEJ. Primary results from SPOTLIGHT highly anticipated! #ASCOGI23 #GI23 https://t.co/Twq8kCdzBV @KoheiShitara (Twitter) - Jan 19, 2023
- || leucovorin calcium / Generic mfg.
Next question: if no bolus, then no leucovorin? (Twitter) - Jan 19, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Keine additive Chemo nach Lebermetastasenchirurgie! Wäre ein klarer Verstoß gegen die aktuellen Leitlinien, weil Datenlage zum Nutzen unklar und unnötige Toxizität (PNP) zu diesem frühen Zeitpunkt. FOLFOX kommt dann früh genug zum Einsatz beim Rezidiv. (Twitter) - Jan 19, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Schwierig. Hohes Rezidivrisiko einerseits, relativ lange (im Schnitt) Remission anderseits. Würde tendentiell zu FOLFOX tendieren, würde aber versuchen, das sehr offen mit Pat. zu besprechen. Gab es eine präoperative Therapie? (Twitter) - Jan 19, 2023
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial primary completion date: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jan 19, 2023
P2, N=78, Active, not recruiting, Sponsor: Patrick Boland
Trial primary completion date: Dec 2022 --> Jun 2023
- | Tecentriq (atezolizumab) / Roche
Enrollment closed, Mismatch repair, Tumor mutational burden: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - Jan 19, 2023
P3, N=700, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2022 --> Jun 2023 Recruiting --> Active, not recruiting
- |||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, IO biomarker: #GI23 @ASCO What’s another upper GI biomarker to add to the list? Stay tuned: 👇🏾 💡All IHC🔬based 1️⃣HER2 2️⃣MMR 3️⃣CPS-PDL1 4️⃣FGFR2 5️⃣ #CLAUDIN 18.2 (CLDN18.2) 2 press releases recently: @KlempnerSam @mdmanishshah @OncoAlert “🔦SPOTLIGHT: FOLFOX +/- Zolbe 🕯️GLOW: CAPOX +/- Zolbe” (Twitter) - Jan 19, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
I also don’t understand why LV keeps being carried forward in regimens without a bolus ie FOLFIRINOX. I have the same strategy… I keep in the bolus for curative intent therapy but it’s the first thing I drop when we encounter toxicity. (Twitter) - Jan 18, 2023
- | Avastin (bevacizumab) / Roche
Retrospective data, Journal, Metastases: Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study. (Pubmed Central) - Jan 18, 2023
Recruiting --> Active, not recruiting No abstract available
- |||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
New P1/2 trial, Combination therapy, Metastases: Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 18, 2023
P1/2, N=56, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | Enrollment open, Liquid biopsy, MRI, Metastases, Biopsy: Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial) (clinicaltrials.gov) - Jan 18, 2023
P=N/A, N=45, Recruiting, Sponsor: University Hospital, Ghent
No abstract available Not yet recruiting --> Recruiting
- | Stivarga (regorafenib) / Bayer
Enrollment closed, Trial completion date, Combination therapy, Metastases: FOLFIRINOX-R: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (clinicaltrials.gov) - Jan 18, 2023
P1/2, N=13, Active, not recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Not yet recruiting --> Recruiting Completed --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2023
- Development of artificial intelligence–derived histological biomarkers for first-line treatment selection in metastatic pancreatic ductal adenocarcinoma (mPDAC). (Available On Demand; Poster Board No. M10) - Jan 17, 2023 - Abstract #ASCOGI2023ASCO_GI_1003;
First-line treatment is largely influenced by performance status with fit patients more often receiving FOLFIRINOX (FFX) than Gemcitabine+Nab-Paclitaxel (GNP)... AI derived V-FFX and V-GNP morphological signatures were strongly associated with treatment outcomes for first-line FFX and GNP and can potentially aid in the selection of first-line treatment for mPDAC patients.
- |||| Metastases: #GI23 (Sorry - had to take a break) ➡️This is a big year for Upper GI Ca too with the positive, practice changing (❓) Ph 3 SPOTLIGHT trial: ✅Zolbetuximab + mFOLFOX6 as 1⃣st-line Tx for claudin-18.2+/ HER2− advanced gastric/GEJ adenoca 👁️Kohei Shitara, LBA292 @KoheiShitara (Twitter) - Jan 16, 2023
- |||| Clinical: #GI23 ➡️Two more practical updates: ✅The DEEPER trial of FOLFOXIRI➕cetux vs. FOLFOXIRI➕Bev as 1⃣st line Tx for unresectable RAS/RAF WT mCRC 👁️Yu Sunakawa, Abs 120, Pos F17 ✅Kinetics of postop cfDNA in Pts with resected stage I-III CRC 👁️Stacey A. Cohen, Abs 5 (Twitter) - Jan 16, 2023
- |||| Clinical, P3 data: #GI23 ➡️I'm always a little overwhelmed by #Colorectalcancer - but trying my best: ✅Evaluation of RAS-WT mCRC Pts on the Phase III FIRE-4 trial of FOLFIRI/cetuximab who received the first cycle of treatment with chemotherapy only 👁️Sebastian Stintzing, Abs 100, Pos E17 (Twitter) - Jan 16, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Metastases: #GI23 ➡️Two🎯💊abstracts for BTC: ✅A TAPUR study update of Pertuz➕trastuz in BTC Pts w/ERBB2/3 alterations 👁️Tim Cannon, Abs 546, Pos C16 ✅DDR gene alterations in advanced BTC Pts Txed w/2⃣line BSC +/- FOLFOX (ABC-06 trial) 👁️Angela Lamarca, Abs 593, Pos F5 (Twitter) - Jan 16, 2023
- || Graspa (eryaspase) / ERYtech, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Review, Journal, Metastases: Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. (Pubmed Central) - Jan 16, 2023
Irinotecan-based regimens currently offer the greatest promise. Investigations into paradigm-changing agents and combination approaches continue.
- || leucovorin calcium / Generic mfg.
Folinic acid (not folic acid) can supply folate to the brain via an alternate pathway. https://t.co/9Apo3uhKlf 2/ (Twitter) - Jan 14, 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, IO biomarker: AIO-STO-0417: Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 13, 2023
P2, N=262, Active, not recruiting, Sponsor: Institut f
Investigations into paradigm-changing agents and combination approaches continue. Trial completion date: Dec 2022 --> Sep 2023
- | Erbitux (cetuximab) / Eli Lilly, amelimumab (SY101) / Tasly
New P2b trial, Combination therapy, Metastases: A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 13, 2023
P2b, N=84, Not yet recruiting, Sponsor: Shanghai Celfuture Biotech Co., Ltd.
- Investigation of novel therapeutic targets in pancreatic cancer-associated fibrosis (Lecture Hall) - Jan 13, 2023 - Abstract #LCC2023LCC_183;
Furthermore, PORCN-i improves overall survival in clinically-relevant ‘priming’ (transient manipulation of tumour tissue before chemotherapy) and ‘chronic’ (administration alongside chemotherapy) regimens in combination with current standard-of-care Gemcitabine/Abraxane and FOLFIRINOX chemotherapies in an RNF43 mut orthotopic PDX model...Ongoing work includes identification of tumour and stromal biomarkers of response to PORCN-i using cutting-edge in-house spatial transcriptomics tools and single cell transcriptomics. We are assessing the biological activity of PORCN-i in RNF43 mut PC in phase-II monotherapy clinical trials, with comprehensive analysis of recruited PC patients to identify correlates of collective response to targeted therapy.
- |||| Clinical, Surgery: Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, for #resectable #pancreaticcancer (#ESPAC5): https://t.co/F7WLjqs09J (Twitter) - Jan 12, 2023
- ||||| Clinical, Surgery: Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable #PancreaticCancer (ESPAC5): a four-arm, multicentre, randomized, phase 2 trial https://t.co/ToGB8sCNX5 @LancetGastroHep (Twitter) - Jan 12, 2023
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Combination therapy: NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 12, 2023
P2, N=53, Recruiting, Sponsor: University of Florida
We are assessing the biological activity of PORCN-i in RNF43 mut PC in phase-II monotherapy clinical trials, with comprehensive analysis of recruited PC patients to identify correlates of collective response to targeted therapy. Trial primary completion date: Dec 2022 --> Jun 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. (Pubmed Central) - Jan 11, 2023
The rate of febrile neutropenia was higher in the stent group than in the non-stent group. There is a need to assess the patient's condition with discretion and develop a treatment strategy with short prognosis in mind after stent insertion.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy. (Pubmed Central) - Jan 11, 2023
Patient-derived organoids (PDOs) can serve as personalized in vitro models of patient tumors. In this study, PDOs from locally advanced gastric cancers were able to reliably predict resistance to neoadjuvant chemotherapy.
- || Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead, sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, Metastases: Switch Maintenance in Pancreatic (clinicaltrials.gov) - Jan 11, 2023
P1/2, N=46, Recruiting, Sponsor: James Cleary, MD, PhD
In this study, PDOs from locally advanced gastric cancers were able to reliably predict resistance to neoadjuvant chemotherapy. Not yet recruiting --> Recruiting
- || gevokizumab (VPM087) / Novartis
Enrollment closed, Combination therapy, Metastases: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov) - Jan 11, 2023
P1, N=167, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Totally agreed. I also don't advocate for durva being added to FOLFOX. I have seen this somewhere in the WWW. (Twitter) - Jan 10, 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. (Pubmed Central) - Jan 10, 2023
Our findings suggest that induction FOLFIRINOX followed by SBRT in patients with LAPC results in better survival with manageable toxicities. A high total SBRT dose was associated with a high rate of conversion surgery and could afford better survival.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine. (Pubmed Central) - Jan 10, 2023
A high total SBRT dose was associated with a high rate of conversion surgery and could afford better survival. Although genetic screening in precision medicine reduces costs per outcome, according to the willingness-to-pay threshold of $4349.50 in the Iranian health system, add-on cetuximab to the FOLFIRI regimen is not a cost-effective strategy even with genetic screening and a 20% price reduction.
- | Opdivo (nivolumab) / BMS
New P3 trial: A022102: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (clinicaltrials.gov) - Jan 10, 2023
P3, N=382, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
New P2 trial, Combination therapy, Metastases: NuTide:323: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - Jan 10, 2023
P2, N=171, Recruiting, Sponsor: NuCana plc
- | New P2 trial: Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - Jan 10, 2023
P2, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || leucovorin calcium / Generic mfg.
I wonder why folinic acid and not folic. Because folinic gets into the CNS more easily? (Twitter) - Jan 10, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Great work by⭐️fellow @BHuffmanMD Few things to add! These were pts at some point eligible for FOLFIRINOX. ALL ECOG 0,1. Few pts >75 We know in clinic how often families fear dose-reductions & impact on efficacy. Good to normalize these conversations & emphasize goal is QOL (Twitter) - Jan 9, 2023
- || leucovorin calcium / Generic mfg.
PK/PD data, Journal: Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer. (Pubmed Central) - Jan 9, 2023
Different metabolic mechanisms appear to be induced when LV is administered as infusion and bolus injection. Since maximal inhibition of TYMS by the 5-FU metabolite 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) requires excess polyglutamated MeTHF, the results point in favor of the bolus regimen.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Pathological Response Predicts Survival after Pancreatectomy following Neoadjuvant FOLFIRINOX for Pancreatic Cancer. (Pubmed Central) - Jan 9, 2023
Since maximal inhibition of TYMS by the 5-FU metabolite 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) requires excess polyglutamated MeTHF, the results point in favor of the bolus regimen. pathologic response predicts survival after pancreatectomy following neoadjuvant FOLFIRINOX for pancreatic cancer, and adjuvant chemotherapy following neoadjuvant treatment might be beneficial for OS and DFS.
- | methotrexate / Generic mfg., dexmedetomidine / Generic mfg.
Preclinical, Journal: Dexmedetomidine Attenuates Methotrexate-Induced Neurotoxicity and Memory Deficits in Rats through Improving Hippocampal Neurogenesis: The Role of miR-15a/ROCK-1/ERK1/2/CREB/BDNF Pathway Modulation. (Pubmed Central) - Jan 9, 2023
Dex co-treatment reversed the MTX-induced behavioral, biochemical, and histological alterations in the rats. These neuroprotective actions could be partly mediated through modulating the miR-15a/ROCK-1/ERK1/2/CREB/BDNF pathway, which enhances hippocampal neurogenesis.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Great question❗️If the patient has truly MMR deficient colon cancer with a ypT3N0 disease, then historical risk factors we use (LVI/PNI/grade etc…) do not apply ❗️I observe these patients as their prognosis is excellent❗️However, for T4N0, I discuss CAPEOX or FOLFOX ❗️ (Twitter) - Jan 9, 2023
- |||| leucovorin calcium / Generic mfg., hydroxocobalamin (vit B12) / Generic mfg.
You see this MRI, you order a B12 level. It is normal. DON'T STOP. Cobalamin C deficiency myelopathy; kids and rare adults. TREATABLE. Get methylmalonic acid and homocysteine (hint these increase). Rx hydroxocobalamin, betaine, folinic acid, levocarnitine. https://t.co/u3vvMDmbR0 (Twitter) - Jan 9, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Clinical: Wow. Thank you. In practice we almost always switch patients to gem/abra if they progress on FOLFIRINOX and they don’t have any other biomarker driven trmt and vice versa. This really questions that practice. May be BSC is the best option for them rather than more toxic chemo. (Twitter) - Jan 8, 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Metastases: Outcomes Following Treatment with FOLFOX for Patients with Resectable or Potentially Resectable Metastatic Colorectal Cancer: A Population-based Cohort Study. (Pubmed Central) - Jan 8, 2023
These neuroprotective actions could be partly mediated through modulating the miR-15a/ROCK-1/ERK1/2/CREB/BDNF pathway, which enhances hippocampal neurogenesis. Oxaliplatin-based chemotherapy for patients with resectable or potentially resectable mCRC with extrahepatic metastases was safe and resulted in similar outcomes in appropriately selected patients when compared with patients with liver-only metastases.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Tecentriq (atezolizumab) / Roche
Clinical: ATOMIC (Alliance A021502) which evaluates FOLFOX alone or combined with atezolizumab for stg 3 colon cancer with dMMR has met its accrual goal of 700 patients!! Many thanks to all for supporting this important trial. Stay tuned. (Twitter) - Jan 7, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: I do as well - agree if any issues with 5FU or break from 26h infusions…low threshold and not entirely convinced of the incremental value of FOLFIRI over irinotecan alone in mCRC (or mGC) for pts who have progressed on FOLFOX. (Twitter) - Jan 7, 2023
- | Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. (Pubmed Central) - Jan 7, 2023
P2
In summary, we report the final overall survival of the AVETUX trial and propose T cell clonality and diversity as a potential marker to predict response to chemo-immunotherapy combinations in MSS mCRC by performing a central radiological review. ClinicalTrials.gov, identifier (NCT03174405).